Gilead Sciences Inc. has been asked by two U.S. senators to explain how it priced its $84,000 hepatitis C treatment Sovaldi, adding pressure on the drugmaker to explain the cost of the breakthrough treatment.
Republican Senator Chuck Grassley of Iowa and Democratic Senator Ron Wyden of Oregon asked Gilead Chief Executive Officer John Martin to give details on the drug $1,000-a-pill price within 60 days. Wyden leads the Senate Finance Committee, which oversees the U.S. health programs Medicare and Medicaid.
Read More